Wednesday, April 1, 2009
Stress management techniques
The word stress means different things to different people. Some people define stress as events or situations that cause them to feel tension, pressure, or negative emotions such as anxiety and anger. Others view stress as the response to these situations.
This response includes physiological changes—such as increased heart rate and muscle tension—as well as emotional and behavioral changes. However, most psychologists regard stress as a process involving a person’s interpretation and response to a threatening event.
Stress is a common experience. We may feel stress when we are very busy, have important deadlines to meet, or have too little time to finish all of our tasks. Often people experience stress because of problems at work or in social relationships, such as a poor evaluation by a supervisor or an argument with a friend.
Some people may be particularly vulnerable to stress in situations involving the threat of failure or personal humiliation. Others have extreme fears of objects or things associated with physical threats—such as snakes, illness, storms, or flying in an airplane—and become stressed when they encounter or think about these perceived threats. Major life events, such as the death of a loved one, can cause severe stress.
Stress can have both positive and negative effects. Stress is a normal, adaptive reaction to threat. It signals danger and prepares us to take defensive action. Fear of things that pose realistic threats motivates us to deal with them or avoid them. Stress also motivates us to achieve and fuels creativity.
Although stress may hinder performance on difficult tasks, moderate stress seems to improve motivation and performance on less complex tasks. In personal relationships, stress often leads to less cooperation and more aggression.
If not managed appropriately, stress can lead to serious problems. Exposure to chronic stress can contribute to both physical illnesses, such as heart disease, and mental illnesses, such as anxiety disorders.
The field of health psychology focuses in part on how stress affects bodily functioning and on how people can use stress management techniques to prevent or minimize disease.
Sources of Stress
Some events, such as the death of a loved one, are stressful for everyone. But in other situations, individuals may respond differently to the same event—what is a stressor for one person may not be stressful for another.
For example, a student who is unprepared for a chemistry test and anticipates a bad grade may feel stress, whereas a classmate who studies in advance may feel confident of a good grade. For an event or situation to be a stressor for a particular individual, the person must appraise the situation as threatening and lack the coping resources to deal with it effectively.
Stressors can be classified into three general categories: catastrophic events, major life changes, and daily hassles. In addition, simply thinking about unpleasant past events or anticipating unpleasant future events can cause stress for many people.
Disturbing flashbacks and nightmares
A catastrophe is a sudden, often life-threatening calamity or disaster that pushes people to the outer limits of their coping capability. Catastrophes include natural disasters.
such as:
- earthquakes
- tornadoes
- fires
- floods
- hurricanes
- wars
- torture
- automobile accidents
- violent physical attacks
- sexual assaults
Catastrophes often continue to affect their victims’ mental health long after the event has ended. For example, in 1972 a dam burst and flooded the West Virginia mining town of Buffalo Creek, destroying the town.
Two years after the disaster, most of the adult survivors continued to show emotional disturbances.
Similarly, most of the survivors of concentration camps in World War II (1939-1945) continued to experience nightmares and other symptoms of severe emotional problems long after their release from the camps.
The most stressful events
For adolescents, the most stressful events are the death of a parent or a close family member, divorce of their parents, imprisonment of their mother or father, and major personal disability or illness. Sometimes, apparently positive events can have stressful components.
For example, a woman who gets a job promotion may receive a higher salary and greater prestige, but she may also feel stress from supervising coworkers who were once peers.
Getting married is usually considered a positive experience, but planning the wedding, deciding whom to invite, and dealing with family members may cause couples to feel stressed.
Everyday living circumstances
Examples of daily hassles include living in a noisy neighborhood, commuting to work in heavy traffic, disliking one’s fellow workers, worrying about owing money, waiting in a long line, and misplacing or losing things.
When taken individually, these hassles may feel like only minor irritants, but cumulatively, over time, they can cause significant stress. The amount of exposure people have to daily hassles is strongly related to their daily mood.
Generally, the greater their exposure is to hassles, the worse is their mood. Studies have found that one’s exposure to daily hassles is actually more predictive of illness than is exposure to major life events.
Tuesday, March 10, 2009
Disposal of Hazardous materials
Abandoned and particularly serious waste sites may qualify as “Superfund” sites, eligible for cleanup with government funding under legislation passed in 1980. In 1993, of about 38,000 hazardous-waste sites inventoried by the Environmental Protection Agency (EPA), 1407 sites were listed on or proposed for the National Priority List (NPL) for waste cleanup.
In 1995 the EPA estimated that 73 million people lived within 4 miles of a Superfund site in the United States. Before 1995, 3300 emergency removals—urgent cleanups of hazardous wastes because of the immediate hazard they present—were conducted.
The serious problem of underground plumes of hazardous materials leaving the original disposal sites has only partial solutions at this time. The typical method of handling this problem is the drilling of wells around a plume's perimeter.
Hazardous materials are then removed from some wells, and water may be injected into other wells to produce a barrier to the plume's motion. Drilling wells and monitoring holes near a toxic site carries risks; a plume originally confined between strata (horizontal layers of rock) may penetrate vertically through a drilled hole and escape confinement.
A recent method of treatment for shallow plumes of chlorinated solvents depends on their chemical reactivity. A trench is dug around the leaking waste site and filled with a mixture of soil and powdered iron. The iron then reacts with the chlorinated solvents, turning them into simple hydrocarbons, which are less hazardous.
Medical Wastes
The best way to eliminate hazardous wastes is not to generate them in the first place. For example, improvements have been made in the production of integrated circuits: The toxic chlorinated hydrocarbons commonly used in the 1970s were replaced in the 1980s by less toxic glycol ethers and in the 1990s by low-toxicity esters and alcohols.
Recycling is the recovery or reuse of usable materials from waste. About 5 percent of hazardous waste in the United States is recycled as solvents; a similar amount is recovered as metals.
For example, approximately 15 percent of sulfuric acid is recycled in chemical manufacturing. In the past, most sulfur used for sulfuric acid production was mined; now the amount of sulfur recovered from smelters (facilities that remove metals from ores), refineries (facilities that purify substances), and manufacturers is more than double that produced by mining.
In the United States, the practice of using industrial wastes, which often contain hazardous wastes, as ingredients in commercial fertilizers is encouraged as a means of recycling hazardous wastes. The safety of this practice has recently been called into question, however, and some states are starting to regulate it.
Friday, March 6, 2009
Progress in the basic sciences and clinical research
Progress in the basic sciences and clinical research is moving scientists closer to identifying vaccine candidates suitable for large-scale HIV vaccine trials. Researchers continue to design and test novel ways to present HIV proteins to the immune system, as well as develop new antigen-adjuvant vaccine formulations.
Although the challenges are daunting, scientists remain hopeful that they can develop safe and effective HIV vaccines. A growing number and variety of experimental vaccines are entering clinical tests in primates and humans, and more trials are exploring whether changing immunization schedules, increasing booster doses, or using a combination vaccine strategy can stimulate stronger, more durable immune responses.
Currently, about 30 NIAID-sponsored preventive HIV vaccine clinical trials are underway or planned for various stages of testing in the United States and internationally. More vaccines will be studied in the next 2 years than in the last 5 years combined, and thousands of additional healthy volunteers from all populations will be needed in the coming years.
Therapeutic AIDS Vaccines
Currently, there are no approved therapeutic vaccines for people infected with HIV. To date, scientists have conducted more than 30 NIAID-funded therapeutic vaccine clinical trials. Additionally, new vaccine candidates are being tested as both potential therapeutic and preventive vaccines.
Therapeutic vaccine research started in the early 1990s with several trials in the United States and Europe in volunteers on antiretroviral therapy (ART). In June 1992, AVEG began its first therapeutic vaccine trial, enrolling 55 HIV-infected men and women. The experimental gp160 vaccine was found to be safe. The first therapeutic vaccine trial enrolling asymptomatic HIV-infected children and HIV-infected pregnant women began in 1993.
The current NIAID-funded network conducting therapeutic vaccine studies is the AIDS Clinical Trials Group (ACTG). The group was created in 1987 as a network of domestic clinical sites to develop therapeutic agents to treat HIV and opportunistic infections and malignancies. By 1991, ACTG was divided to create the Adult ACTG (AACTG) and the Pediatric ACTG (PACTG). As the largest network of its kind in the world, ACTG carries out a broad scientific, therapeutic, and pathogenesis-based research agenda.
Preventive HIV Vaccines
Clinical Trials of Preventive HIV Vaccines
Currently, there are no approved preventive vaccines for HIV infection. Since the first HIV vaccine trial opened in 1987, researchers have studied more than 50 different preventive vaccine candidates in more than 100 NIAID-funded clinical trials.
The first HIV vaccine clinical trial opened in August 1987 at the National Institutes of Health Clinical Center in Bethesda, Maryland. This Phase I trial enrolled 138 healthy, uninfected volunteers. The gp160 subunit candidate vaccine tested caused no serious adverse effects.
Six months later, the NIAID AIDS Vaccine Evaluation Group (AVEG), the first U.S. cooperative HIV vaccine clinical trials group, began enrolling volunteers in its first trial.
In December 1992, NIAID launched its first Phase II HIV vaccine clinical trial.
This trial included uninfected volunteers with a history of high-risk behavior-injection drug use, multiple sex partners, or sexually transmitted infections. Participants were counseled repeatedly to avoid any behaviors that put them at risk of HIV infection.
Created in May 2000, the NIAID-funded HIV Vaccine Trials Network (HVTN) is a network of clinical sites in the United States and abroad dedicated to developing a preventive HIV vaccine by testing and evaluating candidate vaccines in all phases of clinical trials.
The network includes more than 25 sites in the United States, Africa, Asia, South America, and the Caribbean. HVTN's global capacity allows for rapid expansion as more vaccine candidates enter the pipeline for testing and development, and for carrying out large-scale studies of suitable vaccines.
HVTN built upon the many accomplishments of the HIV Prevention Trials Network and AVEG, two former NIAID networks that conducted preparedness and HIV vaccine studies. Scientific creativity, along with collaboration among private industry, academia, and government, are key aspects of HVTN's design.
In addition, NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC) conducts research that facilitates the development of effective vaccines for human disease, with the primary focus of research being the development of vaccines for AIDS. Established in 1997 by former President Bill Clinton as part of an initiative to develop an AIDS vaccine and located in Bethesda,
VRC develops and tests vaccine candidates in all phases of clinical testing.
VRC works with scientists in academic, clinical, and industrial laboratories through a program of national and international collaborations. The center actively seeks industrial partners for the development, efficacy testing, and marketing of vaccines, and focuses on the development of new methodologies and training opportunities that will benefit all HIV vaccine researchers.
Phases of Clinical Trials
A Phase I trial is the first setting in which an experimental HIV vaccine is given to people. The trial, which can last up to 2 years, may enroll between 20 to 100 HIV-uninfected volunteers at low risk for HIV infection.
A Phase I trial primarily seeks information on safety, particularly looking for any vaccine-related side effects. The trial can also provide data on the dose and administration schedule needed to achieve the optimal immune responses.
If the vaccine elicits neutralizing antibodies or cytotoxic T lymphocytes (CTLs), scientists can study whether these responses are broadly protective against a wide variety of HIV strains that scientists refer to as subtypes or clades.
Once Phase I trials show the experimental HIV vaccine is safe, well tolerated, and appears promising, it can advance into Phase II. These trials, which can last longer than 2 years, enroll between 100 to 300 volunteers at high and low risk for acquiring HIV.
In these trials researchers gather more data on safety and immunogenicity.
Investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID) investigators are also developing designs for intermediate trials that can provide preliminary answers about a candidate vaccine's efficacy, and determine if the vaccine candidate should move forward into large Phase III, or efficacy, trials.
A Phase IIb trial, also known as a "proof-of-concept" trial, is smaller, requiring 2,000 to 5,000 volunteers, is less expensive than Phase III trials, and may provide clues about the immune responses that can protect against disease.
The most promising vaccine candidates move into Phase III, enrolling 10,000 or more HIV-uninfected people at high risk for exposure to the virus. A Phase III trial, which can last up to 4 years, is typically designed to ensure enough data are collected on safety and effectiveness to support a license application to FDA.
Thursday, March 5, 2009
AIDS
The symptoms of AIDS are primarily the result of conditions that do not normally develop in individuals with healthy immune systems. Most of these conditions are infections caused by bacteria, viruses, fungi and parasites that are normally controlled by the elements of the immune system that HIV damages.How HIV Is and Is Not Transmitted
HIV is primarily found in the blood, semen, or vaginal fluid of an infected person. HIV is transmitted in 3 main ways:
- Having sex (anal, vaginal, or oral) with someone infected with HIV
- Sharing needles and syringes with someone infected with HIV
- Being exposed (fetus or infant) to HIV before or during birth or through breast feeding.
Risk Factors for HIV Transmission
You may be at increased risk for infection if you have :
- injected drugs or steroids, during which equipment (such as needles, syringes, cotton, water) and blood were shared with others
- had unprotected vaginal, anal, or oral sex (that is, sex without using condoms) with men who have sex with men, multiple partners, or anonymous partners
- exchanged sex for drugs or money
- been given a diagnosis of, or been treated for, hepatitis, tuberculosis (TB), or a sexually transmitted disease (STD) such as syphilis
- received a blood transfusion or clotting factor during 1978–1985
- had unprotected sex with someone who has any of the risk factors listed above
Preventing Transmission
Your risk of getting HIV or passing it to someone else depends on several things. Do you know what they are? You might want to talk to someone who knows about HIV. You can also do the following:
1. Abstain from sex (do not have oral, anal, or vaginal sex) until you are in a relationship with only one person, are having sex with only each other, and each of you knows the other’s HIV status.
- If both you and your partner have HIV, use condoms to prevent other sexually transmitted diseases (STDs) and possible infection with a different strain of HIV.
- If only one of you has HIV, use a latex condom and lubricant every time you have sex.
2. If you have, or plan to have, more than one sex partner, consider the following:
- Get tested for HIV
- If you are a man who has had sex with other men, get tested at least once a year.
- If you are a woman who is planning to get pregnant or who is pregnant, get tested as soon as possible, before you have your baby.
- Talk about HIV and other STDs with each partner before you have sex.
- Learn as much as you can about each partner’s past behavior (sex and drug use), and consider the risks to your health before you have sex.
- Ask your partners if they have recently been tested for HIV; encourage those who have not been tested to do so.
- Use a latex condom and lubricant every time you have sex.
- If you think you may have been exposed to another STD such as gonorrhea, syphilis, or Chlamydia trachomatis infection, get treatment. These diseases can increase your risk of getting HIV.
- Get vaccinated against hepatitis B virus.
3. Even if you think you have low risk for HIV infection, get tested whenever you have a regular medical check-up.
4. Do not inject illicit drugs (drugs not prescribed by your doctor). You can get HIV through needles, syringes, and other works if they are contaminated with the blood of someone who has HIV. Drugs also cloud your mind, which may result in riskier sex.
5. If you do inject drugs, do the following:
- Use only clean needles, syringes, and other works.
- Never share needles, syringes, or other works.
- Be careful not to expose yourself to another person's blood.
- Get tested for HIV test at least once a year.
- Consider getting counseling and treatment for your drug use.
- Get vaccinated against hepatitis A and B viruses.
6. Do not have sex when you are taking drugs or drinking alcohol because being high can make you more likely to take risks.
To protect yourself, remember these ABCs:
A=Abstinence
B=Be Faithful
C=Condoms
Symptoms of HIV Infection
You cannot rely on symptoms alone because many people who are infected with HIV do not have symptoms for many years.
Someone can look and feel healthy but can still be infected. In fact, one quarter of the HIV-infected persons in the United States do not know that they are infected.
HIV Testing
Most HIV tests look for these antibodies rather than the virus itself. There are many different kinds of HIV tests, including rapid tests and home test kits.
All HIV tests approved by the US government are very good at finding HIV.
HIV Epidemiology
Identifying and understanding the risk factors associated with HIV acquisition and transmission, and the development and progression of AIDS in men, women, and adolescents are critical aspects in the fight against this disease. Using epidemiological methods, NIAID-supported investigators are able to address key scientific questions by studying and comparing the effects of HIV in different human populations. Scientific findings gathered from these epidemiological studies help to provide insight on how to prevent the spread of HIV and also improve the quality of life for those already infected.
Clinical Trials and Cohort Studies
One major area of investigation involves studying the patterns of use and the efficacy/effectiveness of therapies in clinical trials and in cohort studies. The dramatic impact of highly active antiretroviral therapy (HAART) on HIV infection has prompted researchers to study the long-term clinical course of HIV infection in persons using HAART. While to date there have been no signs of a decrease in the effectiveness of HAART therapy, widespread drug resistance remains a concern. Furthermore, as people living with HIV continue to live longer, many of these immunocompromised individuals, who will naturally have a higher prevalence of other disease risk factors due to age, may develop other life threatening morbidities, such as heart disease or cancer, at a younger age than their HIV-negative peers. These types of scientific questions are now being investigated through epidemiological research.
International Research
Internationally, research opportunities have been expanding and accelerating in parts of the world that have been severely affected by the epidemic, including Africa, Asia and the Caribbean. Research has expanded as a result of dramatic cost reductions of HAART in many countries and the introduction of the Presidents Emergency Plan for HIV/AIDS Relief (PEPFAR), aimed at expanding access of antiretroviral therapy worldwide. The global availability of HAART has opened doors for studying the best use of therapy in different populations, which is important given that therapeutic regimens for HIV may differ in populations due to other health stressors such as other infectious diseases and nutritional deficits. Research on the availability, use and success of HAART in developing economy nations is now underway and additional research in these settings is being planned.
Goals of NIAID’s HIV/AIDS epidemiology research
- Identifying the proportion of the population affected by HIV and the rate at which new infections are occurring, as well as developing profiles on vital baseline information for HIV-infected populations and populations at risk, in order to evaluate vaccine efficacy and therapeutic clinical trials
- Describing the changing manifestations of the clinical and laboratory course of HIV infection, the changing frequency with which various complications occur, and the impact of therapy on modulating changes in HIV-related survival and clinical outcomes
- Investigating the clinical course of HIV infection among persons with other co-morbidities (i.e., HBV, HCV, tuberculosis, malaria, heart disease, diabetes) to better understand the natural and treated history of the disease in those with other chronic conditions
- Evaluating the patterns of adherence to HAART in populations around the world, the predictors of disease progression, and the efficacy of HAART in populations exposed to a variety of other concomitant infections and under nutritional and other health stressors
- Studying the biological, clinical, and epidemiological characteristics of people who are at high risk for HIV infection but do not become infected and those who are long-term non-progressors.
Source: National Institutes of Health
HIV/AIDS Connections
The acquired immunodeficiency syndrome (AIDS) was first recognized in 1981 and has since become a major worldwide pandemic. Abundant evidence indicates that AIDS is caused by the human immunodeficiency virus (HIV) , which was discovered in 1983. By leading to the destruction and/or functional impairment of cells of the immune system, notably CD4+ T cells, HIV progressively destroys the body's ability to fight infections and certain cancers.
Why is there overwhelming scientific consensus that HIV causes AIDS?
Before HIV infection became widespread in the human population, AIDS-like syndromes occurred extremely rarely, and almost exclusively in individuals with known causes of immune suppression, such as chemotherapy and underlying cancers of certain types.
A marked increase in unusual infections and cancers characteristic of severe immune suppression was first recognized in the early 1980s in homosexual men who had been otherwise healthy and had no recognized cause for immune suppression.
An infectious cause of AIDS was suggested by geographic clustering of cases, links among cases by sexual contact, mother-to-infant transmission, and transmission by blood transfusion. Isolation of the HIV from patients with AIDS strongly suggested that this virus was the cause of AIDS.
Since the early 1980s, HIV and AIDS have been repeatedly linked in time, place and population group; the appearance of HIV in the blood supply has preceded or coincided with the occurrence of AIDS cases in every country and region where AIDS has been noted.
Individuals of all ages from many risk groups – including men who have sex with men, infants born to HIV-infected mothers, heterosexual women and men, hemophiliacs, recipients of blood and blood products, healthcare workers and others occupationally exposed to HIV-tainted blood, and male and female injection drug users – have all developed AIDS with only one common denominator: infection with HIV.
HIV destroys CD4+ T cells, which are crucial to the normal function of the human immune system.
In fact, depletion of CD4+ T cells in HIV-infected individuals is an extremely powerful predictor of the development of AIDS.
Studies of thousands of individuals have revealed that most HIV-infected people carry the virus for years before enough damage is done to the immune system for AIDS to develop; however, with time, a near-perfect correlation has been found between infection with HIV and the subsequent development of AIDS.
Recently developed, sensitive tests have shown a strong correlation between the amount of HIV in the blood and the subsequent decline in CD4+ T cell numbers and development of AIDS. Furthermore, reducing the amount of virus in the body with anti-HIV drugs can slow this immune destruction.
How HIV Causes AIDS
As the virus attacks those cells, the person infected with HIV is less equipped to fight off infection and disease ultimately resulting in the development of AIDS.
Most people who are infected with HIV can carry the virus for years before sufficient damage to the immune system results in the development of AIDS.
However, there is a strong connection between high levels of HIV in the blood and the decline in CD4+ T cells and the development of AIDS.
Antiretroviral medicines can reduce the amount of virus in the body, preserve CD4+ T cells and dramatically slow the destruction of the immune system.
